

Steven E Gryn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6524303/steven-e-gryn-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

862
citations

10
h-index

18
g-index

18
ext. papers

1,103
ext. citations

3.2
avg, IF

3.31
L-index

#	Paper	IF	Citations
16	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 596-624	3.8	139
15	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1902-1906	5.6	9
14	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 506-525	3.8	348
13	Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 525-533	6.1	8
12	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 557-576	3.8	205
11	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1036-1043	3.8	38
10	Statin therapy: time for a precision medicine approach?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 187-192	1.6	0
9	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 24	6	15
8	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 118, 284-91	3.1	18
7	New oral agents for treating dyslipidemia. <i>Current Opinion in Lipidology</i> , 2016 , 27, 579-584	4.4	8
6	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1255-62	4	11
5	Novel therapeutics in hypertriglyceridemia. <i>Current Opinion in Lipidology</i> , 2015 , 26, 484-91	4.4	27
4	Pharmacogenomics, lipid disorders, and treatment options. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 36-47	6.1	20
3	Personalized medicine: importance of clinical interpretative skills for real-world patient care. <i>Personalized Medicine</i> , 2014 , 11, 395-408	2.2	
2	Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 367-9	1.9	14
1	Application of a genomics-guided warfarin dosing nomogram for hospitalized patients. <i>FASEB Journal</i> , 2013 , 27, 673.1	0.9	